# Study of LM-302 in Patients With Advance Solid Tumors

> **NCT05161390** · PHASE1,PHASE2 · COMPLETED · sponsor: **LaNova Medicines Zhejiang Co., Ltd.** · enrollment: 153 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** LM-302 Injection

## Key facts

- **NCT ID:** NCT05161390
- **Lead sponsor:** LaNova Medicines Zhejiang Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-26
- **Primary completion:** 2025-01-10
- **Final completion:** 2025-01-10
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05161390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05161390, "Study of LM-302 in Patients With Advance Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05161390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*